T-cell Lymphoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials